Oncology medical home: ASCO and COA standards
K Woofter, EB Kennedy, K Adelson, R Bowman… - JCO Oncology …, 2021 - ascopubs.org
PURPOSE: To provide Standards on the basis of evidence and expert consensus for a pilot
of the Oncology Medical Home (OMH) certification program. The OMH model is a system of …
of the Oncology Medical Home (OMH) certification program. The OMH model is a system of …
Acute home-based care for patients with cancer to avoid, substitute, and follow emergency department visits: a conceptual framework using Porter's Five Forces
Background Patients with cancer constitute a large and increasing segment of patients who
receive unscheduled hospital-based care due to treatment-related symptoms and disease …
receive unscheduled hospital-based care due to treatment-related symptoms and disease …
[HTML][HTML] A taxonomy of the factors contributing to the overtreatment of cancer patients at the end of life. What is the problem? Why does it happen? How can it be …
Highlights•At the EOL many patients with cancer continue to receive nonbeneficial and often
harmful treatments.•We review the factors that contribute to the overtreatment of patients with …
harmful treatments.•We review the factors that contribute to the overtreatment of patients with …
Risk stratification and outreach to hematology/oncology patients during the COVID-19 pandemic
CK Osterman, T Triglianos, GS Winzelberg… - Supportive Care in …, 2021 - Springer
Purpose Cancer patients have many medical and psychosocial needs, which may increase
during the COVID-19 pandemic. We sought to (1) risk-stratify hematology/oncology patients …
during the COVID-19 pandemic. We sought to (1) risk-stratify hematology/oncology patients …
The problem of cancer drugs costs: a payer perspective
LN Newcomer - The Cancer Journal, 2020 - journals.lww.com
Chemotherapy and supportive drugs constitute 70% of a cancer patient's medical costs
during active therapy. Payers use several approaches to keep those costs affordable …
during active therapy. Payers use several approaches to keep those costs affordable …
[PDF][PDF] Input parameters for value-based alternative payment models in expensive pharmaceuticals in the Western countries: a scoping review and an use case …
JFH Eijsink, U Plantinga, C Boersma… - … pharmaceutical care at … - research.rug.nl
Background The budget impact of expensive drugs in Western countries rises, because of
new expensive innovative treatments. From population, hospital and patient perspectives …
new expensive innovative treatments. From population, hospital and patient perspectives …
[引用][C] Practice considerations for participation in the enhancing oncology model
BR Bourbeau, K Hagerty, N Dickson, B Polite… - JCO Oncology …, 2022 - ascopubs.org
On June 27, 2022, the Centers for Medicare and Medicaid Services'(CMS) and Center for
Medicare and Medicaid Innovation (CMMI) released the Enhancing Oncology Care Model …
Medicare and Medicaid Innovation (CMMI) released the Enhancing Oncology Care Model …
[引用][C] Collaborating: A Pathway for Better Cancer Care
LN Newcomer - JCO Oncology Practice, 2020 - ascopubs.org
Of all the concepts and changes described in the updated Patient-Centered Oncology
Payment (PCOP) model by Ward et al 1 in JCO Oncology Practice, none is more important …
Payment (PCOP) model by Ward et al 1 in JCO Oncology Practice, none is more important …
[引用][C] A Better Path to Value in Cancer Care
HD Miller - JCO Oncology Practice, 2020 - ascopubs.org
A high-value health care system would ensure that patients with cancer and other diseases
receive both the most effective treatments available and adequate supportive care, all at the …
receive both the most effective treatments available and adequate supportive care, all at the …